In vivo efficacy was tested in an imiquimod (IMQ)-induced psoriasis mouse model treated with TA ointment (5% and 10%), and the outcomes were evaluated using the psoriasis area and severity index (PASI), histopathology, blood routines, and blood biochemical examinations.<h4>Results</h4>TA selectively inhibited the reductase activity of the b' domain of PDI and induced non-covalent conformational changes, reducing hydrophobicity and chaperone function. Here, P4HB is linked to psoriasis.